---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108835"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:20:47.953216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q2 revenue down 39% to $86k; net loss widens to $1.9M; plans to exit ClearUP, focus on biopharma

## Summary
- Revenue $86k (-39% YoY); net loss $1.9M vs $1.3M in Q2 2024; cash $1.2M at June 30.
- Raised $0.9M post-quarter; $7M committed via preferred equity; no debt on balance sheet.
- Plans to exit ClearUP consumer healthtech by year-end; shifts resources to TLR5 agonist Entolimod.
- Extended Entolimod license to include neutropenia; completed study visits for ncVNS device.
- Named Lisa Wolf as permanent CFO; expanded biopharma team with regulatory and clinical staff.

## SEC filing metadata
- accession: 0000950170-25-108835
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/0000950170-25-108835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/tivc-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108835
- JSON: https://secwatch.observer/filing/0000950170-25-108835.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.